Segment Information

9 Months Ended

Sep. 30, 2011

Segment Information

Note 11 – Segment Information

The Company’s financial information broken down by reportable segment was as follows (in thousands):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2011			2010			2011			2010
Revenues
Pharmaceutical Manufacturing - China	$	15,513.0		$	16,384.5		$	49,806.0		$	51,528.7
Cell Therapy - United States		2,177.0			61.1			5,837.0			157.6
Regenerative Medicine - China		66.1			30.0			215.0			30.0
	$	17,756.1		$	16,475.6		$	55,858.0		$	51,716.3
Loss from operations
Pharmaceutical Manufacturing - China	$	717.9		$	2,552.6		$	3,480.1		$	9,302.3
Cell Therapy - United States		(2,996.1	)		(2,304.6	)		(9,957.7	)		(6,917.2	)
Regenerative Medicine - China		(681.8	)		(321.9	)		(1,847.1	)		(1,058.7	)
Corporate office		(4,420.3	)		(5,669.9	)		(17,049.7			(13,181.4	)
	$	(7,380.3	)	$	(5,743.8	)	$	(25,374.4	)	$	(11,855.0	)
Total assets	September 30, 2011			December 31, 2010
Pharmaceutical Manufacturing - China	$	124,045.0		$	125,458.1
Cell Therapy - United States		28,445.4			1,101.9
Regenerative Medicine - China		2,640.0			4,949.8
Corporate office		13,084.3			11,514.9
	$	168,214.7		$	143,024.7